SAB Biotherapeutics (SABS) grants CMO 2.4M stock options with 4-year vest

Rhea-AI Filing Summary

SAB Biotherapeutics reported an insider equity award for its Chief Medical Officer, Alexandra Kropotova. On February 3, 2026, she received a stock option grant covering 2,400,000 shares of common stock under the company’s 2021 Omnibus Equity Incentive Plan.

The option has an exercise price of $4.45 per share. The underlying shares vest over four years: one quarter of the grant vests on the first anniversary of the grant date, and the remaining three quarters vest in 36 equal monthly installments thereafter. Following this grant, she beneficially holds options on 2,400,000 shares, all directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kropotova Alexandra

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.45	02/03/2026		A		2,400,000(1)		(2)	02/03/2036	Common Stock	2,400,000	$0	2,400,000	D

Explanation of Responses:

1. Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

2. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

	/s/ Alexandra Kropotova	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SAB Biotherapeutics (SABS) report for its CMO?

SAB Biotherapeutics reported a stock option grant to Chief Medical Officer Alexandra Kropotova. She received options for 2,400,000 shares of common stock on February 3, 2026, as part of the company’s 2021 Omnibus Equity Incentive Plan, as amended.

How many SAB Biotherapeutics (SABS) stock options were granted to the CMO?

The Chief Medical Officer received options to purchase 2,400,000 shares of SAB Biotherapeutics common stock. These options are documented as a single derivative security award, fully reflected as directly owned following the reported transaction in the Form 4 filing.

What is the exercise price of the SAB Biotherapeutics (SABS) options granted to the CMO?

The stock options granted to the Chief Medical Officer carry an exercise price of $4.45 per share. This means she may purchase SAB Biotherapeutics common shares at $4.45 when options vest and are exercised, subject to the vesting schedule and plan rules.

How do the SAB Biotherapeutics (SABS) CMO stock options vest over time?

The options vest over four years. One quarter of the underlying shares vests on the one-year anniversary of the February 3, 2026 grant date. The remaining three quarters then vest in 36 equal monthly installments, providing gradual vesting through the fourth year.

Under which equity plan were the SAB Biotherapeutics (SABS) CMO options granted?

The options to purchase 2,400,000 SAB Biotherapeutics shares were granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended. This plan governs the terms of equity awards, including stock options, issued to eligible officers and other participants.

Does the SAB Biotherapeutics (SABS) CMO hold these stock options directly or indirectly?

The Form 4 reports that the 2,400,000 stock options are held with direct ownership. There is no indication of indirect ownership through entities such as trusts or partnerships, so the award is attributed directly to the Chief Medical Officer personally.